Amneal Pharmaceuticals, Inc. (AMRX) Stock Price & How to Invest

Amneal Pharmaceuticals is a Bridgewater, New Jersey based biopharmaceutical company with a portfolio of roughly 300 complex generic, specialty, and biosimilar medicines that fill more than 160 million prescriptions a year, mostly in the United States. The business runs in three segments: Affordable Medicines (retail generics, injectables, and biosimilars, the largest at roughly 58% of revenue), Specialty (branded neurology and endocrinology treatments including Parkinson's disease and migraine, around 17% of revenue), and AvKARE (distribution to US federal, retail, and institutional customers, roughly 25% of revenue).

The investment picture centers on a mix shift. Traditional generics face relentless pricing pressure and thin margins, so Amneal is leaning into complex injectables, specialty branded drugs, and biosimilars, which carry higher margins but also higher development costs and manufacturing complexity. Recent results show that shift gaining traction, with Specialty growing fast and adjusted EBITDA rising, but the company also carries a sizable debt load and is spending to expand its biosimilars platform, including the Kashiv BioSciences acquisition, which closed on August 10, 2026. The result is a growth-plus-deleveraging story rather than a pure defensive generics play.

The 2026 results have kept that story on track. Second-quarter net revenue was about $796 million, up about 10% from a year earlier, with net income of about $58 million (up from about $22 million) and adjusted EBITDA of about $206 million, up about 12%. Adjusted EPS of $0.30 beat the $0.23 consensus, the fourth straight quarterly beat, and management raised full-year revenue guidance for the second time, to about $3.10 to $3.20 billion. In September the FDA approved Amneal's lanreotide injection, a generic rival to Ipsen's Somatuline Depot, and the company launched it right away. The company also filed a shelf registration after its Q2 report.

Amneal carries meaningful leverage, with total debt of about $2.8 billion against about $131 million of cash at the end of June 2026, plus an added $350 million term loan for Kashiv, which amplifies both upside and downside and limits financial flexibility. Core generics face persistent pricing pressure, patent litigation from branded rivals, and thin margins that have compressed across the industry. Biosimilars are capital-intensive and face steep list-price erosion once competitors launch, plus shifting FDA guidance and IRA-related dynamics that complicate returns. The Kashiv acquisition, closed in August 2026, adds integration and execution risk, the post-earnings shelf registration leaves room for new share issuance, and much of the equity value assumes the specialty and biosimilar transition keeps compounding. Any slowdown in approvals, launches, or margin gains would pressure both the growth thesis and the deleveraging path.

7 analysts publish price targets on AMRX, averaging $22.71 against a $19.18 price as of October 2026, or +18.4%. The published targets run from $20.00 to $27.00, a moderate spread, and the ratings split 7 buy, 0 hold, 0 sell. Over the last six months there have been 4 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full AMRX forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Amneal Pharmaceuticals, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Specialty and biosimilar mix shift. Amneal is steering revenue toward higher-margin Specialty (neurology, migraine, endocrinology) and complex biosimilars, with Specialty revenue up about 17% year over year in Q2 2026, helped by CREXONT and the BREKIYA autoinjector. The most optimistic published target, $27.00, assumes this works close to its best case.

The case against. Amneal carries meaningful leverage, with total debt of about $2.8 billion against about $131 million of cash at the end of June 2026, plus an added $350 million term loan for Kashiv, which amplifies both upside and downside and limits financial flexibility. The most pessimistic target, $20.00, is roughly what AMRX is worth if this bites instead.

Read the full bull and bear case on AMRX, including what would have to change to break either one. Walnut is not an investment adviser.

No. Amneal Pharmaceuticals, Inc. (AMRX) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Amneal Pharmaceuticals, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$3.1B
• Q2 2026 net revenue: ~$796M (up ~10% YoY)
• Q2 2026 adjusted EBITDA: ~$206M (up ~12% YoY)
• Q2 2026 adjusted EPS: ~$0.30 (vs ~$0.23 expected)
• 2026 revenue guidance: ~$3.10B to $3.20B (raised twice)
• P/E (trailing / forward): ~39x / ~16x
• Market cap: ~$6.7B
• Total debt: ~$2.8B (cash ~$131M)

After nearly doubling over the past year, Amneal trades at about 39 times trailing GAAP earnings but about 16 times 2027 consensus EPS of roughly $1.19, a gap that reflects fast-rising profits from a low base. EV/EBITDA is about 13 times, and enterprise value sits well above market cap because of roughly $2.8 billion of debt. The valuation leans on the specialty and biosimilar mix shift continuing after the Kashiv close.

Other names that sit close to AMRX: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get AMRX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so AMRX sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where AMRX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

AMRX is a leveraged generics maker trying to remix toward higher-margin specialty and biosimilar drugs, a transition story where execution and the balance sheet matter as much as the top line.

Whether AMRX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is AMRX a buy or a sell?, and where the stock could go from here in the AMRX stock forecast.

For income investors, whether AMRX pays a dividend and how the payout looks is covered in does AMRX pay a dividend? And to weigh AMRX against a peer, read the full side-by-side comparisons: AMRX vs VTRS and AMRX vs CNS.